@misc{10481/97144,
year = {2024},
month = {11},
url = {https://hdl.handle.net/10481/97144},
abstract = {Objective The objective of this randomized controlled clinical trial (RCT) was to compare the frequency of early implant
failure, postoperative infection, and pain/inflammation and the degree of implant stability between healthy non-penicillinallergic
individuals receiving a single prophylactic dose of 600 mg clindamycin versus 2 g amoxicillin at 1 h before implant
surgery.
Materials and methods A single-center double-blinded RCT study with parallel groups was undertaken. Eighty-two patients
fulfilled study inclusion criteria and were randomly assigned to the amoxicillin (n = 41) or clindamycin (n = 41) group. The
primary outcome variable was early implant failure. The presence of infection was evaluated immediately after surgery and
on days 7, 14, 30, and 90, and postoperative pain/inflammation was assessed daily on days 1 to 7 post-surgery. Resonance
frequency analysis was used to measure primary and secondary implant stability.
Results One early implant failure was observed (1/81), in a patient from the amoxicillin group. No statistically significant
between-group differences were observed in early implant failure rate, postoperative infection rate up to 90 days, pain/
inflammation scores during the first week post-surgery, or primary or secondary stability values.
Conclusions A single dose of 600 mg clindamycin before implant surgery does not increase the risk of early implant failure
or infection.
Clinical relevance These findings suggest that a single dose of 600 mg clindamycin at 1 h before implant surgery is a safe
antibiotic prophylactic approach; however, when a more prolonged antibiotic therapy is required, it appears advisable to
prescribe an alternative antibiotic to avoid adverse effects.},
abstract = {Objective The objective of this randomized controlled clinical trial (RCT) was to compare the frequency of early implant
failure, postoperative infection, and pain/inflammation and the degree of implant stability between healthy non-penicillinallergic
individuals receiving a single prophylactic dose of 600 mg clindamycin versus 2 g amoxicillin at 1 h before implant
surgery.
Materials and methods A single-center double-blinded RCT study with parallel groups was undertaken. Eighty-two patients
fulfilled study inclusion criteria and were randomly assigned to the amoxicillin (n = 41) or clindamycin (n = 41) group. The
primary outcome variable was early implant failure. The presence of infection was evaluated immediately after surgery and
on days 7, 14, 30, and 90, and postoperative pain/inflammation was assessed daily on days 1 to 7 post-surgery. Resonance
frequency analysis was used to measure primary and secondary implant stability.
Results One early implant failure was observed (1/81), in a patient from the amoxicillin group. No statistically significant
between-group differences were observed in early implant failure rate, postoperative infection rate up to 90 days, pain/
inflammation scores during the first week post-surgery, or primary or secondary stability values.
Conclusions A single dose of 600 mg clindamycin before implant surgery does not increase the risk of early implant failure
or infection.
Clinical relevance These findings suggest that a single dose of 600 mg clindamycin at 1 h before implant surgery is a safe
antibiotic prophylactic approach; however, when a more prolonged antibiotic therapy is required, it appears advisable to
prescribe an alternative antibiotic to avoid adverse effects.},
organization = {Master of Oral Surgery and
Implant Dentistry, School of Dentistry, University of Granada, Spain},
organization = {Master of Oral Surgery and
Implant Dentistry, School of Dentistry, University of Granada, Spain},
publisher = {Springer Nature},
keywords = {Clindamycin},
keywords = {Clindamycin},
keywords = {Amoxicillin},
keywords = {Amoxicillin},
keywords = {Implant failure},
keywords = {Implant failure},
title = {Effects of clindamycin and amoxycillin as prophylaxis against early implant failure: double-blinded randomized clinical trial},
doi = {10.1007/s00784-024-06050-1},
author = {Pradillo-Gallego, Diego and Manzano-Moreno, Francisco Javier and Ocaña-Peinado, Francisco Manuel and Olmedo Gaya, María Victoria},
}